Efficacy and safety of momelotinib in myelofibrosis: A systematic review and meta-analysis with a focus on anemia outcomes

Results from a systematic review and meta-analysis suggest that momelotinib may improve anemia-related outcomes and quality of life in patients with myelofibrosis without increased adverse events. Six studies were included in the meta-analysis (including the large phase 3 trials SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM); momelotinib was noninferior to ruxolitinib in spleen volume reduction but was superior in anemia benefits, increasing transfusion independence and reducing transfusion burden. Symptom burden reduction was similar with momelotinib to other JAK inhibitors.